These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 9127465)

  • 21. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss.
    Heikkinen JE; Selander KS; Laitinen K; Arnala I; Väänänen HK
    J Bone Miner Res; 1997 Jan; 12(1):103-10. PubMed ID: 9240732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease.
    Brown JE; McCloskey EV; Dewar JA; Body JJ; Cameron DA; Harnett AN; Ruutu M; Purohit OP; Tähtelä R; Coleman RE
    Calcif Tissue Int; 2007 Nov; 81(5):341-51. PubMed ID: 17874331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid suppression of bone resorption marker levels with ibandronate therapy in a bisphosphonate-naïve population.
    Sebba AI; Broy S; Kohles JD; Weissman P
    J Clin Densitom; 2008; 11(3):417-23. PubMed ID: 18456528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women.
    Cosman F; Nieves J; Woelfert L; Shen V; Lindsay R
    J Bone Miner Res; 1998 Jun; 13(6):1051-5. PubMed ID: 9626638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The utility of changes in serum levels of C-terminal telopeptide of type I collagen in predicting patient response to oral monthly ibandronate therapy.
    Hochberg MC; Silverman SL; Barr CE; Miller PD
    J Clin Densitom; 2010; 13(2):181-9. PubMed ID: 20347369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease.
    Coleman RE; Purohit OP; Black C; Vinholes JJ; Schlosser K; Huss H; Quinn KJ; Kanis J
    Ann Oncol; 1999 Mar; 10(3):311-6. PubMed ID: 10355575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis.
    Guañabens N; Parés A; Alvarez L; Martínez de Osaba MJ; Monegal A; Peris P; Ballesta AM; Rodés J
    J Bone Miner Res; 1998 Apr; 13(4):731-8. PubMed ID: 9580479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis.
    Ravn P; Neugebauer G; Christiansen C
    Bone; 2002 Jan; 30(1):320-4. PubMed ID: 11792604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of intermittent slow-release sodium fluoride and continuous calcium citrate therapy on calcitropic hormones, biochemical markers of bone metabolism, and blood chemistry in postmenopausal osteoporosis.
    Zerwekh JE; Padalino P; Pak CY
    Calcif Tissue Int; 1997 Oct; 61(4):272-8. PubMed ID: 9312196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys.
    Smith SY; Recker RR; Hannan M; Müller R; Bauss F
    Bone; 2003 Jan; 32(1):45-55. PubMed ID: 12584035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine.
    Gertz BJ; Shao P; Hanson DA; Quan H; Harris ST; Genant HK; Chesnut CH; Eyre DR
    J Bone Miner Res; 1994 Feb; 9(2):135-42. PubMed ID: 8140926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppression.
    Binkley N; Silverman SL; Simonelli C; Santiago N; Kohles JD; Dasic G; Sunyecz JA
    Osteoporos Int; 2009 Sep; 20(9):1595-601. PubMed ID: 19145396
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of antiresorptive effect of hormone therapy and ibandronate in postmenopausal osteoporotic women by assessing type I collagen C-telopeptide levels.
    Srividhya NB; Singh N; Goel N; Gambhir JK; Rathi V; Rajaram S
    Post Reprod Health; 2015 Jun; 21(2):48-55. PubMed ID: 25792627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Biological markers of bone metabolism].
    Delmas PD
    Presse Med; 1993 Feb; 22(6):263-8. PubMed ID: 8511145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral 1,25-dihydroxyvitamin D administration in osteoporotic women: effects of estrogen therapy.
    Cosman F; Nieves J; Shen V; Lindsay R
    J Bone Miner Res; 1995 Apr; 10(4):594-600. PubMed ID: 7610930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment.
    Ravn P; Christensen JO; Baumann M; Clemmesen B
    Bone; 1998 May; 22(5):559-64. PubMed ID: 9600792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlations of serum prolidase activity between bone turnover markers and mineral density in postmenopausal osteoporosis.
    Verit FF; Geyikli I; Yazgan P; Celik A
    Arch Gynecol Obstet; 2006 Jun; 274(3):133-7. PubMed ID: 16532321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.